Navigation Links
GenVec Reports Fourth Quarter And 2012 Year-End Financial Results
Date:3/22/2013

GAITHERSBURG, Md., March 22, 2013 /PRNewswire/ -- Today GenVec, Inc. (NASDAQ: GNVC) announced financial results for the fourth quarter and year ended December 31, 2012.  For the year ended December 31, 2012, the Company reported a net loss of $14.1 million, or $1.09 per share, compared with a net loss of $7.4 million, or $0.58 per share, for the year ended December 31, 2011. GenVec ended the year with $15.3 million in cash, cash equivalents, and short-term investments. 

"In 2012 we continued to make progress in our hearing restoration program, partnered with Novartis, and advanced the development of our product pipeline and core technologies," stated Cynthia Collins , GenVec's President and CEO.  "Other changes implemented since my joining GenVec in May were reducing our workforce to preserve capital and discontinuing spending on non-funded programs.  We continue to seek sources of non-dilutive funding to advance our programs and to reduce expenses to preserve cash."

2012 and Recent Corporate HighlightsHearing Restoration

  • We extended our Research Collaboration and License Agreement with Novartis.  Under the extension, Novartis will fund research at GenVec through January 2014 to support its hearing loss and balance disorders program.
  • RSV Vaccine

  • GenVec conducted a successful pre-IND interaction with the U.S. Food and Drug Administration (FDA) to obtain guidance on the development plan for its vaccine against respiratory syncytial virus (RSV).  The outcome of the pre-IND interaction was obtaining clarification on the nonclinical, clinical, and chemistry, manufacturing, and control (CMC) requirements that need to be met in order to submit an acceptable IND.
     
  • GenVec received a grant of approximately $590,000 over two years from the Natio
    '/>"/>

  • SOURCE GenVec, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. GenVec To Release First Quarter 2012 Financial Results And Conduct A Conference Call On May 10, 2012
    2. GenVec Appoints Cynthia Collins as President and CEO
    3. GenVec Reports Inducement Award
    4. GenVec Announces Conditional Approval of FMD Vaccine for Cattle
    5. GenVec to Release Second Quarter 2012 Financial Results and Conduct a Conference Call on August 9, 2012
    6. GenVec Reports Second Quarter 2012 Financial Results
    7. GenVec Reports Third Quarter 2012 Financial Results
    8. GenVec to Present at 25th Annual ROTH Conference
    9. GenVec To Release Fourth Quarter And Year-end 2012 Financial Results And Conduct A Conference Call On March 22, 2013
    10. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
    11. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ...
    (Date:1/15/2014)... 2014  In an unprecedented effort to curb the spread of "superbugs" ... transport vehicles, an advanced and portable UV germicidal lamp manufactured by ... time. In order to prevent EMS paramedics and ... West Palm Beach Fire Rescue is the first ...
    (Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
    Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
    (Date:4/23/2014)... by a researcher from the Cancer Science Institute of ... has identified the cancer specific stem cell which causes ... developing new drugs for the treatment of this disease ... led by Dr Chan Shing Leng, Research Assistant Professor ... a cancer-specific variant of a cell surface protein, CD44v8-10, ...
    (Date:4/23/2014)... known as Ritalin, may prevent the depletion of self-control, ... a journal of the Association for Psychological Science. , ... or trying to focus attention on a boring textbook ... potential explanation for this difficulty: Exerting self-control for a ... self-control effectively on subsequent tasks. , "It is as ...
    (Date:4/22/2014)... leaders visited the New Jersey Institute of Technology ... Bloom for the launch of the New Jersey ... a new model for business innovation through the ... and investment. U.S. Senator Cory Booker, Panasonic Corp. ... New Jersey Lieutenant Governor Kim Guadagno, New Jersey ...
    (Date:4/22/2014)... April 22, 2014 Researchers at UT Southwestern ... suffering from depression . , A team ... mechanism by which ghrelin (a hormone with natural anti-depressant ... a potentially powerful new treatment for depression in the ... , The study, published online in April,s issue ...
    (Date:4/22/2014)... 2014) The International Communication Association will hold ... Washington. The theme of the 2014 conference will ... networked and digital society. , Featuring over 2,300 ... 2,200 Communication scholars representing over 40 countries, the ... conference in the world. This year,s conference features ...
    Breaking Medicine News(10 mins):Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:ADHD drug may help preserve our self-control resources 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2
    ... 2010 (Portland, Ore.) A new study finds that ... up to a year and the program can also save ... most common eating disorder in the country, affecting more than ... few treatment options are available. But a first-of-a-kind study ...
    ... upon estrogens to survive and proliferate in about 70% ... treatment to fight this variety of tumours relies on ... of therapy develops in more than 30% of the ... resistance to tamoxifen is thus essential to develop new ...
    ... ... of Consumers Consider Apples a Value-Based Anytime Food for Both Adults and Children; ,Shoppers ... ... than three-out-of-four Americans, apples and apple beverages fill the dual purpose of being a ...
    ... gastric cancer patients who have had part or all ... post-operative weight loss and improve appetite, according to a ... of the American Gastroenterological Association (AGA) Institute. "It ... the side effects of gastrectomy. Our study provides convincing ...
    ... ... , ... 2010 -- Pat Heyward Canes, a new provider of fashion forward walking canes , ... women ranging from classic to whimsical. Made from performance materials, the canes can withstand ...
    ... ... key management to PCI compliance efforts , ... Salt Lake City, UT (Vocus) March 31, 2010 -- Venafi, ... the security risks they face when encryption keys are not properly monitored and managed., ...
    Cached Medicine News:Health News:Short-term program for binge eaters has long-term benefits 2Health News:Short-term program for binge eaters has long-term benefits 3Health News:How breast cancer cells evade therapeutic attacks 2Health News:Apples Are the New Superfruit 2Health News:Apples Are the New Superfruit 3Health News:Apples Are the New Superfruit 4Health News:Promising hormone may help reduce malnutrition in gastric cancer patients 2Health News:Pat Heyward Canes Unveils New Stylish Walking Cane Collection Just in Time for Mother's Day 2Health News:PCI Compliance and Data Security Requires Private Key Management – New Industry White Paper Explains 2
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    Medicine Products: